Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Alfa eCare in connection with the acquisition of 2BRA
Mandate

Vinge advises Main Capital and Alfa eCare in connection with the acquisition of 2BRA

January 02, 2023 Employment and Benefits IT, Telecommunications and Outsourcing Intellectual Property M&A Life Sciences & Health

The Alfa eCare group is a recognized and rapidly growing software provider within the e-health sector that offers solutions to both private and public healthcare providers in the Nordics.

2BRA System AB was founded in 2008 and develops business systems used for labour market measures and initiatives. The company’s services are provided companies that support people in establishing themselves in the labor market and to municipalities, where the company’s system today is used in over 100 municipal operatios. The acquisition of 2BRA is the sixth acquisition by the Alfa eCare group since Main Capital became majority owners of the group in 2020.

Vinge’s team advising Main Capital and Alfa eCare mainly consisted of Filip Öhrner, Linus Adolfsson, Jonna Skog (M&A), Elin Broman (Employment), Lisa Hörnqvist (IT and GDPR), Rebecka Målquist, Johan Gavelin (IP) and Ottilia Pettersson (project assistant).

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024